TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 121 filers reported holding TCR2 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $2,702 | +35.1% | 1,801 | +33.4% | 0.00% | – |
Q4 2022 | $2,000 | +100.0% | 1,350 | +69.2% | 0.00% | – |
Q3 2022 | $1,000 | -50.0% | 798 | 0.0% | 0.00% | – |
Q2 2022 | $2,000 | 0.0% | 798 | 0.0% | 0.00% | – |
Q1 2022 | $2,000 | -33.3% | 798 | +6.5% | 0.00% | – |
Q4 2021 | $3,000 | -62.5% | 749 | -16.8% | 0.00% | – |
Q3 2021 | $8,000 | +33.3% | 900 | +147.9% | 0.00% | – |
Q2 2021 | $6,000 | +500.0% | 363 | +725.0% | 0.00% | – |
Q1 2021 | $1,000 | 0.0% | 44 | +120.0% | 0.00% | – |
Q4 2020 | $1,000 | – | 20 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |